Granylocyte transfusion: a controlled study in patients with acuute nonlymphocytic leukemia

Transfusion
I E FortunyJ J McCullough

Abstract

Granulocyte transfusions are frequently used during the leukopenic phase of induction chemotherapy for acute nonlymphocytic leukemia (ANLL) although no controlled study has documented their usefulness. We have compared the morbidity and mortality of febrile episodes in granulocytopenic (less than 500/mm3) adults with ANLL who received granulocytes and those who did not. Granulocytes were obtained from related normal donors using a continuous flow centrifuge. Seventeen patients who received 98 transfusions during 23 febrile episodes were compared with 22 patients who received no granulocytes during 35 febrile episodes. No significant difference in clearing of documented infection occurred between the transfused (71%) or the control (76%) group. Granulocytes did not result in more rapid termination of febrile episodes nor in significant decrease in fever 24 hours following the transfusion. Factors contributing to the lack of obvious clincal benefit are discussed.

References

Aug 24, 1972·The New England Journal of Medicine·R G GrawE S Henderson
Jun 1, 1969·The American Journal of the Medical Sciences·G P BodeyJ K Luce
May 13, 1971·The New England Journal of Medicine·S SchimpffA Serpick
Mar 1, 1972·Transfusion·I DjerassiW Ciesielka
Aug 1, 1967·The American Journal of Medicine·L SchwarzenbergJ R Schlumberger
Jul 1, 1965·Journal of Applied Physiology·R Alexanian, D M Donohue
Feb 28, 1964·Annals of the New York Academy of Sciences·E J FREIREICHE E MORSE
Jul 12, 1965·JAMA : the Journal of the American Medical Association·E M HERSHE J FREIREICH

❮ Previous
Next ❯

Citations

Jan 1, 1979·CRC Critical Reviews in Clinical Laboratory Sciences·J McCullough
Jan 1, 1982·Medical and Pediatric Oncology·R F ReissJ Kulpa
Jul 27, 2004·Bone Marrow Transplantation·S P Robinson, D I Marks
Jan 1, 1981·Critical Reviews in Clinical Laboratory Sciences·C R Valeri
Jan 1, 1983·Journal of Clinical Apheresis·L GlasserT H Price
Jan 1, 1995·Journal of Clinical Apheresis·R G Strauss
Jan 1, 1997·Journal of Clinical Apheresis·E C Vamvakas, A A Pineda
Sep 14, 2001·Vox Sanguinis·T Yeghen, S Devereux
Jan 1, 1989·Cancer Investigation·J P Dutcher
Apr 19, 2006·Journal of Clinical Apheresis·Thomas H Price
May 8, 1980·The New England Journal of Medicine·M S RosensheinD C Dale
Dec 2, 2005·Current Opinion in Hematology·Ehab Atallah, Charles A Schiffer
Nov 30, 2004·British Journal of Haematology·M Bishton, R Chopra
Mar 6, 2009·Journal of Pediatric Hematology/oncology·Alan S GrahamThomas V Brogan
Apr 30, 2016·The Cochrane Database of Systematic Reviews·Lise J EstcourtEdwin Massey
Jan 1, 1977·Acta Medica Scandinavica·B Lantz, P Reizenstein
Feb 1, 1981·European Journal of Pediatrics·H PfliegerE Kleihauer
Sep 1, 2006·Medical Mycology·Charles A Schiffer
Nov 1, 1991·Anaesthesia and Intensive Care·J D Tobias, C Schleien
Jun 1, 1978·Clinics in Haematology·T A Lister, R A Yankee
Sep 17, 2017·Cytotherapy·Juan Gea-Banacloche

❮ Previous
Next ❯

Related Concepts

Related Feeds

AML: Role of LSD1 by CRISPR (Keystone)

Find the latest rersearrch on the ability of CRISPR-Cas9 mutagenesis to profile the interactions between lysine-specific histone demethylase 1 (LSD1) and chemical inhibitors in the context of acute myeloid leukemia (AML) here.

Acute Myeloid Leukemia

Acute myeloid leukemia (AML) is a clinically and genetically heterogeneous disease with approximately 20,000 cases per year in the United States. AML also accounts for 15-20% of all childhood acute leukemias, while it is responsible for more than half of the leukemic deaths in these patients. Here is the latest research on this disease.